Patterns Of Treatment And Retreatment Of Acute Attacks Of Hereditary Angioedema (Hae) With Standard Of Care (Soc) On-Demand Medication: Results From The Apex-2 Study
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY(2020)
Abstract
Berotralstat (BCX7353), administered orally once daily, is an inhibitor of plasma kallikrein in development for prophylaxis of HAE. Efficacy over a 24-week period was evaluated in the Phase 3, randomized, double-blind, placebo-controlled APeX-2 study (NCT03485911). This exploratory analysis evaluated use of SOC on-demand medications. Subjects with HAE Type 1/2 and ≥2 attacks in the 14-56 day baseline period were randomized 1:1:1 to berotralstat 110mg:berotralstat 150mg:placebo daily for 24 weeks. Subjects were to treat HAE attacks according to their usual treatment plan. Retreatment was defined as use of >1 dose of SOC on-demand medication to treat an attack. SOC on-demand medications were used in 87.2% of attacks. Of these, Firazyr® SC, Berinert® IV, Cinryze® IV, and Ruconest® IV were used first-line in 53.0%, 29.3%, 10.8%, and 6.9% of attacks, respectively. Overall, 17.3% of attacks were retreated with the same or another SOC on-demand medication (11.4%, 14.5%, and 24.2% of attacks in the 110mg, 150mg, and placebo arms, respectively). Retreatment was most common when Firazyr was used first-line, with 26.9% of attacks retreated. Firazyr was the most frequently used SOC on-demand medication for HAE attacks and had the highest rate of retreatment. The percentage of attacks retreated with SOC on-demand medications was lower for the daily oral 110mg and 150mg berotralstat arms than in the placebo arm, suggesting reduced attack severity on berotralstat.
MoreTranslated text
Key words
hereditary angioedema,acute attacks,medication,on-demand
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined